Antitumor necrosis factor treatment for pediatric inflammatory bowel disease

Authors

  • Charlotte I. de Bie MD,

    1. Department of Pediatric Gastroenterology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands
    Search for more papers by this author
  • Johanna C. Escher MD, PhD,

    1. Department of Pediatric Gastroenterology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands
    Search for more papers by this author
  • Lissy de Ridder MD, PhD

    Corresponding author
    1. Department of Pediatric Gastroenterology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands
    • Erasmus MC-Sophia Children's Hospital, Pediatric Gastroenterology, Department of Pediatrics, Dr. Molewaterplein 60, 3015 GJ, Rotterdam, the Netherlands
    Search for more papers by this author

  • Conflict of interest: the second and last author have participated in the REACH study by inclusion of patients (initiated by Centocor). The company did not play any role in the writing of this article.

Abstract

Infliximab, adalimumab, and certolizumab are monoclonal antibodies against tumor necrosis factor-α (TNFα), a proinflammatory cytokine with an increased expression in the inflamed tissues of inflammatory bowel disease (IBD) patients. Currently, infliximab is the only anti-TNF drug that has been approved for use in refractory pediatric Crohn's disease (CD). Nevertheless, adalimumab and certolizumab have been used off-label to treat refractory pediatric IBD. Over the past 10 years, anti-TNF treatment has been of great benefit to many pediatric IBD patients, but their use is not without risks (infections, autoimmune diseases, malignancies). Despite the growing experience with these drugs in children with IBD, optimal treatment strategies still need to be determined. The purpose of this review is to summarize the current knowledge on the use of anti-TNF drugs in pediatric IBD and to discuss the yet-unsolved issues. (Inflamm Bowel Dis 2011;)

Ancillary